NCT07024407View on ClinicalTrials.gov

A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 14, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions

Heterotopic Ossification (HO)

Interventions

DRUG

Andecaliximab

Participants will receive weekly subcutaneous injections of andecaliximab during inpatient hospitalization, clinic visit, or self-administration if discharged from the hospital

Trial Locations (1)

80113

RECRUITING

Craig Hospital, Denver

All Listed Sponsors

lead

Ashibio Inc

INDUSTRY

NCT07024407 - A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton. | Biotech Hunter | Biotech Hunter